Skip to main content
Premium Trial:

Request an Annual Quote

Pyrosequencing Q2 Revenues Rise

NEW YORK, Aug. 7 – Pyrosequencing, of Uppsala, Sweden, said on Tuesday that its second-quarter revenues jumped to $2.3 million, compared to $580,000 in the year-ago period.

The SNP company said the increase came from the sale of 20 of its PSQ 96 Systems during the quarter compared to nine instruments sold in the same quarter one year ago. 

The company also reported an increased net loss to $3.2 million, or 9 cents per share, compared with $2.5 million, or 10 cents a share, in the year-ago period.

At the end of June, the company had $67.1 million in cash, cash equivalents, and investments in high-grade debt securities, including investments with maturity dates exceeding 12 months.

Last month, a research group at Uppsala University had agreed to use Pyrosequencing technology to examine the genomes of antibiotic resistant bacteria, according to the company.

As GenomeWeb  reported, the deal calls for an Uppsala researcher to use several applications of the Pyrosequencing technology to analyze antibiotic resistant strains of Helicobacter pylori and Mycobacterium tuberculosis , the bacteria responsible for gastric ulcers and tuberculosis, respectively. 

Pyrosequencing will provide technical support throughout the collaboration, which will last one year.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.